LyGenesis
A clinical-stage cell therapy company that transforms a patient's lymph nodes into bioreactors capable of growing functioning ectopic organs.
Launch date
Employees
Market cap
-
Enterprise valuation
€69—104m (Dealroom.co estimates Oct 2023.)
Pittsburgh Pennsylvania (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
$3.0m | Series A | ||
$4.0m | Debt | ||
$11.0m | Convertible | ||
* | $19.0m | Series A | |
| Total Funding | €30.0m | ||
Related Content
Recent News about LyGenesis
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.